Study guide
13.3 Colorectal Cancer & Osteoporosis Screening
AMCB Certified Nurse-Midwife CNM
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Early Pregnancy — Diagnosis, History, Dating & Models of Care
1.1 Signs of Pregnancy, hCG Kinetics & Acceptance of Pregnancy 1.2 Prenatal History, Obstetric Notation & Gestational Dating 1.3 The Initial Prenatal Laboratory Panel 1.4 Prenatal Genetic Screening, Diagnostic Testing & Hereditary Risk 1.5 Models of Prenatal Care, Birth-Setting Counseling & Community Referral
2 Chapter 2: Ongoing Prenatal Assessment, Nutrition & Common Discomforts
2.1 Prenatal Visit Cadence, Milestone Screening & Fundal Height 2.2 Leopold Maneuvers, Fetal Heart Auscultation & Antepartum Surveillance 2.3 Clinical Pelvimetry & Assessment of the Bony Pelvis 2.4 Maternal Nutrition, Weight Gain & Immunization in Pregnancy 2.5 Nausea, Vomiting & Gastrointestinal Discomforts of Pregnancy 2.6 Musculoskeletal, Vascular & Neurologic Discomforts of Pregnancy
3 Chapter 3: Hypertensive, Endocrine & Hematologic Complications of Pregnancy
3.1 Classification & Diagnosis of Hypertensive Disorders of Pregnancy 3.2 Acute Severe Hypertension, Magnesium Sulfate & Eclampsia 3.3 Delivery Timing, Aspirin Prophylaxis & Postpartum Hypertension 3.4 Gestational Diabetes: Pathophysiology, Screening & Diagnosis 3.5 Glycemic Management, Fetal Surveillance & Delivery Timing in Gestational Diabetes 3.6 Thyroid Disorders & Anemia in Pregnancy
4 Chapter 4: Bleeding, Amniotic Fluid Disorders, Preterm Birth & Perinatal Loss
4.1 First-Trimester Bleeding, Early Pregnancy Loss & Gestational Trophoblastic Disease 4.2 Ectopic Pregnancy: Diagnosis & Management 4.3 Third-Trimester Bleeding & Amniotic Fluid Volume Disorders 4.4 Preterm Labor & Preterm Prelabor Rupture of Membranes 4.5 Intrauterine Fetal Demise, Stillbirth & Bereavement Care
5 Chapter 5: Normal Labor, Birth & Intrapartum Fetal Surveillance
5.1 Onset of Labor, True Versus False Labor & Nutrition in Labor 5.2 The First and Second Stages of Labor 5.3 Cardinal Movements, Third & Fourth Stages of Labor 5.4 Cord Clamping, Cord Blood, Cord Gases & Placental Examination 5.5 Fetal Oxygenation, Intermittent Auscultation & Uterine Activity Monitoring 5.6 Electronic Fetal Monitoring Parameters & the NICHD Categories 5.7 Intrauterine Resuscitation, Scalp Electrode & Amnioinfusion
6 Chapter 6: Labor Support, Analgesia, Induction & Augmentation
6.1 The Midwifery Model, Continuous Labor Support & Non-Pharmacologic Comfort 6.2 Water Immersion, Waterbirth & Non-Supine Birth Positions 6.3 Systemic, Neuraxial & Regional Analgesia in Labor 6.4 Indications & Timing for Induction of Labor 6.5 The Bishop Score & Cervical Ripening Methods 6.6 Oxytocin Titration, Tachysystole Management & Amniotomy
7 Chapter 7: Intrapartum Emergencies, Malpresentation & Perineal Repair
7.1 Shoulder Dystocia: Recognition & the HELPERR Protocol 7.2 Dystocia Complications, Umbilical Cord Prolapse & Intraamniotic Infection 7.3 Malposition, Manual Rotation, Breech, Face Presentation & Nuchal Cord 7.4 Perineal Anatomy & Classification of Obstetric Lacerations 7.5 Episiotomy & Surgical Perineal Repair 7.6 TOLAC, VBAC & Uterine Rupture
8 Chapter 8: The Normal Puerperium, Postpartum Assessment & Lactation
8.1 Puerperal Physiology, Uterine Involution & Lochia 8.2 The BUBBLE-HE Postpartum Assessment 8.3 Bladder, Bowel & Perineal Care and the Postpartum Care Continuum 8.4 Lactation Neuroendocrinology & the Stages of Lactogenesis 8.5 LATCH Assessment, Latch Biomechanics & Adequate Intake 8.6 Lactation Complications, Medication Safety & Contraindications
9 Chapter 9: Postpartum Contraception, Family Planning & Hemorrhage
9.1 Return of Fertility, Lactational Amenorrhea & US MEC in the Puerperium 9.2 Postpartum Hormonal Contraception & Intrauterine Devices 9.3 Barrier & Permanent Contraception, Postpartum Sexuality & Family Support 9.4 Postpartum Hemorrhage: Definition, Shock Recognition & Quantitative Blood Loss 9.5 The Four Ts: Etiology of Postpartum Hemorrhage 9.6 Hemorrhage Resuscitation, Uterotonics, TXA & Surgical Escalation
10 Chapter 10: Puerperal Infection, Thromboembolism, Cesarean Recovery & Perinatal Mental Health
10.1 Puerperal Endometritis & Septic Pelvic Thrombophlebitis 10.2 Puerperal Wound Infection, Mastitis & Breast Abscess 10.3 Postpartum Venous Thromboembolism 10.4 Post-Cesarean Recovery: Inpatient Care & Care After Discharge 10.5 Postpartum Blues, Depression & EPDS Screening 10.6 Treating Postpartum Depression, Anxiety, OCD & Psychosis
11 Chapter 11: Neonatal Transition, Resuscitation & the Newborn Examination
11.1 Fetal-to-Neonatal Transition & Circulatory Remodeling 11.2 APGAR Scoring & the NRP Initial Steps 11.3 Positive Pressure Ventilation, MR. SOPA & Advanced Resuscitation 11.4 Newborn Vital Signs, Anthropometrics & the Ballard Score 11.5 Cranial Assessment & Head-to-Chest Examination 11.6 Genitourinary & Musculoskeletal Examination and Primitive Reflexes
12 Chapter 12: Newborn Prophylaxis, Screening, Common Disorders & Care Through 28 Days
12.1 Standard Neonatal Prophylaxis: Vitamin K, Eye Ointment & Hepatitis B 12.2 Universal Newborn Screening: Hearing, CCHD & Dried Blood Spot 12.3 Neonatal Hypoglycemia, Thermoregulation & the Infant of a Diabetic Mother 12.4 Neonatal Hyperbilirubinemia & Phototherapy 12.5 Infant Feeding Education, Circumcision Counseling & Care Through 28 Days
13 Chapter 13: Well-Woman Preventive Care, Cancer Screening & Immunization
13.1 The Well-Woman Visit & Cervical Cancer Screening 13.2 ASCCP Risk-Based Management & Breast Cancer Screening 13.3 Colorectal Cancer & Osteoporosis Screening 13.4 Adult Immunization & Environmental and Occupational Exposure Screening
14 Chapter 14: Contraception, Abortion Care & Fertility Evaluation
14.1 Contraceptive Efficacy Tiers & Long-Acting Reversible Contraception 14.2 Combined Hormonal Contraception 14.3 Progestin-Only Methods & Emergency Contraception 14.4 Abortion Care: Options Counseling, Medication Abortion & Follow-Up 14.5 Initial Infertility Evaluation & Gynecologic Imaging Referral
15 Chapter 15: Benign Gynecologic Conditions, Pelvic Floor & Menstrual Disorders
15.1 Endometriosis & Adenomyosis 15.2 Pelvic Organ Prolapse & Urinary Incontinence 15.3 Adnexal Masses, Malignancy Red Flags & Vulvar Disease 15.4 The Normal Menstrual Cycle & Anticipatory Guidance 15.5 The FIGO PALM-COEIN Classification of Abnormal Uterine Bleeding 15.6 Evaluating Abnormal Uterine Bleeding & the Amenorrhea Workup 15.7 Polycystic Ovary Syndrome
16 Chapter 16: Vaginitis, Sexually Transmitted Infections, Sexual Health & Menopause
16.1 Differential Diagnosis of Vaginitis & Bacterial Vaginosis 16.2 Candidiasis, Trichomoniasis, Chlamydia & Gonorrhea 16.3 Pelvic Inflammatory Disease 16.4 Genital Herpes, Syphilis & Anogenital Warts 16.5 Sexual Health Assessment, Sexual Function & Care After Sexual Assault 16.6 Reproductive Aging, Menopause Definitions & Clinical Manifestations 16.7 Menopausal Hormone Therapy 16.8 Non-Hormonal Therapies & Postmenopausal Osteoporosis
17 Chapter 17: Primary Care — Chronic Disease & Common Acute Conditions
17.1 Midwifery Primary Care Scope & Hypertension Management 17.2 Antihypertensive Pharmacotherapy & Hyperlipidemia 17.3 Type 2 Diabetes & Thyroid Disease in Primary Care 17.4 Respiratory Infections, Asthma & Urinary Tract Infection 17.5 Gastrointestinal & Dermatologic Conditions 17.6 Mental Health Screening & Substance Use Disorders 17.7 Intimate Partner Violence, Reproductive Coercion & Human Trafficking
18 Chapter 18: Midwifery Scope of Practice, Ethics, Collaboration & Health Equity
18.1 Regulatory Foundation of Practice & the Midwifery Model of Care 18.2 Bioethics, Informed Refusal & Collaborative Practice 18.3 Maternal Health Disparities, Structural Racism & Inclusive Care
13.3 Colorectal Cancer & Osteoporosis Screening
Key Takeaways Explain This Topic AI
Average-risk colorectal cancer screening begins at age 45, with colonoscopy every 10 years or annual fecal immunochemical testing among the accepted options.
Any positive non-colonoscopy screening test must be followed by diagnostic colonoscopy, not by repeating the stool test.
WHO criteria define osteopenia as a T-score between minus 1.0 and minus 2.5 and osteoporosis as minus 2.5 or lower.
DEXA screening is recommended for all women at 65 and older, and for younger postmenopausal women with fracture risk factors identified by a tool such as FRAX.
Weight-bearing and resistance exercise plus adequate calcium and vitamin D form the non-pharmacologic foundation of prevention.
Last updated: September 2026
Colorectal Cancer (CRC) Screening Guidelines
Colorectal adenocarcinoma arises predominantly from pre-existing adenomatous polyps (adenoma-to-carcinoma sequence) over a 10- to 15-year developmental window, providing an ideal target for preventive polypectomy and early detection.
USPSTF Screening Schedule
Routine Screening for Ages 45 to 75 Years: The USPSTF recommends routine colorectal cancer screening for all average-risk adults beginning at age 45 years and continuing through age 75 years (Grade A for ages 50-75, Grade B for ages 45-49).
Selective Screening for Ages 76 to 85 Years: Screening should be individualized based on the patient's overall health, prior screening history, and life expectancy (Grade C recommendation). Routine screening is not recommended after age 85.
Recommended Screening Modalities & Intervals
Screening Modality Testing Interval Advantages & Procedural Realities Follow-Up Requirement
Colonoscopy Every 10 Years Direct full mucosal visualization from rectum to cecum; diagnostic and therapeutic (allows immediate polypectomy); gold standard. Requires bowel prep and conscious sedation. Surveillance interval shortened to 3-5 years if high-risk adenomas or multiple polyps are detected.
Fecal Immunochemical Test (FIT) Annually High sensitivity for human hemoglobin in lower GI tract; non-invasive; low cost; no dietary or medication restrictions (unlike guaiac tests). ANY positive FIT mandates prompt diagnostic colonoscopy.
Stool DNA-FIT (sDNA-FIT / Cologuard) Every 3 Years Combines FIT hemoglobin detection with molecular assays for abnormal methylated DNA biomarkers shed by neoplasms. Higher sensitivity for adenomas than FIT alone, but higher false-positive rate. ANY positive sDNA-FIT mandates prompt diagnostic colonoscopy.
Flexible Sigmoidoscopy Every 5 Years (or q10y if combined with annual FIT) Visualizes distal colon and rectum (splenic flexure); limited bowel prep; no sedation required. Misses proximal colon lesions (40-50% of neoplasms). Any polyp detected mandates full colonoscopy.
CT Colonography (Virtual Colonoscopy) Every 5 Years Non-invasive helical CT imaging of air-insufflated colon. Detects polyps ≥6 mm. Requires full bowel prep. Extracolonic incidental findings common; any lesion ≥6 mm mandates colonoscopy.
[!CRITICAL] AMCB Board Rule on Stool Testing: Non-invasive stool-based tests (FIT or sDNA-FIT) are purely screening tools. If a stool test returns positive , it is NEVER appropriate to repeat the stool test . A positive test indicates occult blood or neoplastic DNA; repeating the test delays diagnosis and introduces sampling error. The patient must be referred directly for a diagnostic colonoscopy .
Osteoporosis Screening & Bone Mineral Density Assessment
Osteoporosis is a systemic skeletal disorder characterized by low bone mineral density (BMD) and microarchitectural deterioration of bone tissue, leading to bone fragility and susceptibility to low-trauma "fragility fractures" (vertebral compression fractures, femoral neck/hip fractures, and distal radius/Colles fractures). The postmenopausal decline in circulating estradiol accelerates osteoclast-mediated bone resorption relative to osteoblast bone formation.
Dual-Energy X-Ray Absorptiometry (DEXA) Indications
Universal Screening at Age 65: The USPSTF and the National Osteoporosis Foundation recommend routine DEXA screening for all women aged 65 years and older , regardless of clinical risk factors.
Selective Screening in Younger Postmenopausal Women (<65 Years): Screening is recommended for postmenopausal women younger than 65 if their formal clinical fracture risk assessment demonstrates a risk equal to or greater than that of a 65-year-old white woman with no additional risk factors. This is quantified as a FRAX 10-year probability of a major osteoporotic fracture ≥8.4% (or a 10-year probability of hip fracture ≥3.0%).
Clinical Risk Factors Triggering Early Screening: Low body weight (<127 lbs / 57.6 kg or BMI <21 kg/m²), prior adult fragility fracture, parental history of hip fracture, current cigarette smoking, excessive alcohol consumption (≥3 drinks daily), chronic systemic corticosteroid therapy (≥5 mg prednisone equivalent daily for ≥3 months), rheumatoid arthritis, premature ovarian insufficiency (<40 years), or secondary causes (hyperthyroidism, celiac disease, malabsorption).
T-Score Diagnostic Criteria (WHO Standard)
The T-score compares the patient's measured BMD to the mean BMD of a healthy, young adult female reference population, expressed in standard deviations (SD): T-Score = Patient’s Measured BMD − Young Adult Mean BMD Young Adult Standard Deviation \text{T-Score} = \frac{\text{Patient's Measured BMD} - \text{Young Adult Mean BMD}}{\text{Young Adult Standard Deviation}} T-Score = Young Adult Standard Deviation Patient’s Measured BMD − Young Adult Mean BMD
Diagnostic Category T-Score Criteria (Lumbar Spine, Femoral Neck, or Total Hip) Clinical Interpretation & Midwifery Management
Normal Bone Mass T-score ≥ -1.0 SD Routine preventive counseling: calcium 1,200 mg/day, vitamin D 800–1,000 IU/day, regular weight-bearing exercise. Repeat DEXA in 5 to 15 years.
Osteopenia (Low Bone Mass) T-score between -1.0 and -2.5 SD Calculate 10-year fracture risk via FRAX. If 10-year major osteoporotic fracture risk is ≥20% OR hip fracture risk is ≥3.0% , initiate pharmacotherapy. Repeat DEXA in 2 to 5 years.
Osteoporosis T-score ≤ -2.5 SD Formal diagnostic threshold. Warrants evaluation for secondary causes (calcium, phosphorus, 25-OH-D, TSH, creatinine) and initiation of pharmacotherapy (oral bisphosphonates).
Severe / Established Osteoporosis T-score ≤ -2.5 SD PLUS history of ≥1 fragility fracture High imminent fracture risk. Anabolic therapy or potent antiresorptive pharmacotherapy indicated.
Note on Z-Scores: The Z-score compares BMD to age-, sex-, and ethnicity-matched peers. A Z-score ≤ -2.0 SD in a premenopausal woman is defined as "below the expected range for age" and mandates investigation for secondary causes (endocrinopathies, malabsorption, celiac disease, multiple myeloma).
Midwifery Management & Prevention of Bone Loss
Elemental Calcium: 1,200 mg daily for all women aged 51 and older (dietary sources preferred). If supplements are required: calcium carbonate (40% elemental calcium, requires gastric acid; take with meals) or calcium citrate (21% elemental calcium, acid-independent; preferred in patients taking PPIs, H2 blockers, or with achlorhydria).
Vitamin D3 (Cholecalciferol): 800 to 1,000 IU daily (target serum 25-hydroxyvitamin D level ≥30 ng/mL).
Lifestyle Interventions: Regular weight-bearing exercise (walking, jogging, tennis) and progressive resistance strength training; complete smoking cessation; limiting alcohol intake to <2 drinks per day; comprehensive home fall-prevention evaluation.
Pharmacologic Therapy: Indicated for women with a T-score ≤ -2.5, those with a hip or vertebral fragility fracture regardless of T-score, or those with osteopenia and FRAX scores exceeding the treatment threshold (≥20% major fracture or ≥3% hip fracture). First-line therapy: Oral bisphosphonates (alendronate 70 mg weekly or risedronate 35 mg weekly). Patient Instructions: Take immediately upon awakening with 8 oz of plain water, on an empty stomach; remain completely upright for at least 30 to 60 minutes before ingesting any food, beverage, or other medications to prevent esophageal ulceration.